Business Context and Reporting Period
This Form 8-K filing by Nuvation Bio Inc. (NUVB) was submitted on March 9, 2021, reporting events occurring on that date. The company is a Delaware corporation with principal executive offices in New York, NY, and its Class A Common Stock and Redeemable Warrants trade on the New York Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments rather than financial performance metrics.
Material Changes
The primary material change reported is the adjustment to the compensation package for David Hung, M.D., President and Chief Executive Officer, effective January 1, 2021:
- Base Salary Increase: Raised from $475,000 to $550,000.
- Bonus Structure: Target bonus percentage remains at 75% of base salary.
- Equity Grants:
- Option to purchase 165,465 shares of Class A common stock under the 2021 Equity Incentive Plan, vesting over four years.
- Option to purchase 224,760 shares of Class A common stock under the Plan, vesting pursuant to the Long Term Incentive Program.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is limited to the disclosure of the CEO's compensatory arrangements approved by the Board of Directors.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2021 Equity Incentive Plan to assess dilution impact.
- Confirm the specific vesting milestones and performance criteria for the Long Term Incentive Program grant.
- Review the company's cash position to ensure it can support the increased annual salary obligation.
- Check for any related party transaction disclosures regarding Dr. Hung's other holdings or roles.